Impact of different patterns of metastasis in non-small-cell lung cancer patients
- PMID: 33508966
- DOI: 10.2217/fon-2020-0587
Impact of different patterns of metastasis in non-small-cell lung cancer patients
Abstract
Aim: The aim of this study was to evaluate the frequency and median time for the development of metastases and prognosis by metastatic site after the diagnosis of non-small-cell lung cancer (NSCLC). Patients & methods: This cohort study was conducted with 1096 patients diagnosed with NSCLC between 2006 and 2014. Results: The most prevalent site of NSCLC metastases was the respiratory system. The nervous and adrenal systems presented the longest median time for the development of metastases. The 6-month survival varied from 68.2% for liver to 79.9% for the nervous system. Bone metastases were associated with a higher risk of death. Conclusion: The respiratory system was the most prevalent site of metastases. OS and risk of death varied according to the metastatic site.
Keywords: frequency; metastases; non-small-cell lung cancer; survival.
Similar articles
-
Site of Metastases as Prognostic Factors in Unselected Population of Stage IV Non-Small Cell Lung Cancer.Asian Pac J Cancer Prev. 2018 Jul 27;19(7):1907-1910. doi: 10.22034/APJCP.2018.19.7.1907. Asian Pac J Cancer Prev. 2018. PMID: 30051671 Free PMC article.
-
Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database.Cancer Med. 2021 Jan;10(2):471-482. doi: 10.1002/cam4.3562. Epub 2020 Dec 15. Cancer Med. 2021. PMID: 33320433 Free PMC article.
-
Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study.Future Oncol. 2021 Jul;17(19):2461-2473. doi: 10.2217/fon-2021-0103. Epub 2021 Mar 12. Future Oncol. 2021. PMID: 33706557
-
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis.J Thorac Oncol. 2010 Jan;5(1):23-8. doi: 10.1097/JTO.0b013e3181c41e8d. J Thorac Oncol. 2010. PMID: 19934774
-
Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1485-9. doi: 10.1097/JTO.0b013e318267223a. J Thorac Oncol. 2012. PMID: 22982649
Cited by
-
STRIP2 motivates non-small cell lung cancer progression by modulating the TMBIM6 stability through IGF2BP3 dependent.J Exp Clin Cancer Res. 2023 Jan 13;42(1):19. doi: 10.1186/s13046-022-02573-1. J Exp Clin Cancer Res. 2023. PMID: 36639675 Free PMC article.
-
Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.Eur J Orthop Surg Traumatol. 2024 Aug;34(6):2823-2833. doi: 10.1007/s00590-024-04018-1. Epub 2024 Jun 5. Eur J Orthop Surg Traumatol. 2024. PMID: 38836904
-
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.Int J Mol Sci. 2022 Jun 20;23(12):6832. doi: 10.3390/ijms23126832. Int J Mol Sci. 2022. PMID: 35743275 Free PMC article. Review.
-
Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases.Curr Issues Mol Biol. 2024 Nov 24;46(12):13443-13455. doi: 10.3390/cimb46120802. Curr Issues Mol Biol. 2024. PMID: 39727930 Free PMC article. Review.
-
Prognostic significance of bone metastasis and clinical value of bone radiotherapy in metastatic non-small cell lung cancer receiving PD-1/PD-L1 inhibitors: results from a multicenter, prospective, observational study.Transl Lung Cancer Res. 2024 Oct 31;13(10):2603-2616. doi: 10.21037/tlcr-24-441. Epub 2024 Oct 18. Transl Lung Cancer Res. 2024. PMID: 39507037 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical